Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Functional Correlates of Intelligence Quotient and Cognitive Abilities Vary According to Maturation in Pediatric MS
Multiple Sclerosis
P9 - Poster Session 9 (5:30 PM-6:30 PM)
3-013

Clinical and cognitive features of pediatric MS patients differ from adults. The effect of brain maturation on RS FC and its possible interaction with cognitive features has never been studied.

To test maturation effects on neuropsychological profiles and resting state (RS) functional connectivity (FC) in cognitive and motor networks of pediatric patients with multiple sclerosis (MS).

Seventy-six pediatric MS patients underwent a neuropsychological assessment of Wechsler-Intelligence-Scales for Intelligent Quotient (IQ), Semantic/Phonemic Verbal Fluency Test (SVFT/PVFT), Symbol Digit Modalities Test (SDMT), Coding Design (CD) and Block Design (BD) subtests, Trial Making Test (TMT-A/B). In 58 right-handed MS patients and 22 matched healthy controls (HC), RS FC within basal ganglia, executive, language, sensorimotor, and default-mode networks was estimated. Maturation effects were tested by splitting pediatric MS in those below the age of 16 years (B16) (n=46) and those above or equal 16 years (A16) (n=30).

Most patients (81.6%) achieved IQ scores within or above average values (median IQ=97.5). The highest rate of failure was observed in CD (21.1%), TMT-B (15.8%), TMT-A (10.5%), and SDMT (9.2%). Compared to HC, pediatric MS patients showed reduced RS FC in all networks, mainly involving the caudate nucleus and its connections with cingulate, prefrontal, and sensorimotor cortices. This effect was particularly relevant in younger patients (B16), where reduced basal ganglia, language and executive RS FC was associated with poorer cognitive performances (r range=0.37/0.48), while reduced cingulate RS FC was associated with a lower IQ (r=0.36). In older patients (A16), reduced language and executive RS FC was correlated with lower IQ and CD, BD and PVFT/SVFT scores (r range=0.42-0.67). However, A16 patients also presented increased executive, default-mode and language RS FC vs HC, which was detrimental on performance at the same tests (r range=-0.39/-0.62).

Maturation significantly impacts on RS FC abnormalities and on their association with cognitive performances.
Authors/Disclosures
Laura Cacciaguerra, MD, PhD (Mayo Clinic)
PRESENTER
Ms. Cacciaguerra has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Ms. Cacciaguerra has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BMS Celgene. Ms. Cacciaguerra has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Ms. Cacciaguerra has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BIOMEDIA.
Maria Assunta Rocca (Neuroimaging Research Unit) Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche. Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. The institution of Maria Assunta Rocca has received research support from MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
Chiara Curatoli, Other (Università vita salute San Raffaele) Dr. Curatoli has nothing to disclose.
Carmen Vizzino Carmen Vizzino has nothing to disclose.
Monica Margoni Monica Margoni has received research support from MAGNIMS. Monica Margoni has received research support from Merck-Serono. Monica Margoni has received research support from Sanofi-Genzyme.
Paola Valsasina Paola Valsasina has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ACCMED.
Massimo Filippi, MD, FAAN (Ospedale San Raffaele, Neuroimaging Research Unit) Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi;. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi- Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.